Payment overview · 2025
General Payments
$605.40
34 reported records · 19 companies
Healthcare provider profile · identity verified
Scott Michael Luneau, MD
Allopathic & Osteopathic Physicians|Hospitalist · SOUTHERN PINES, NC · NPI 1972665529
Verified facts
What the public records show
CMS Open Payments records show Scott Michael Luneau, MD received $605.40 in general payments during 2025 across 34 reported records.
Grifols USA, LLC accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $84.28 | 13.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.34 | 11.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.46 | 7.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.36 | 6.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.82 | 6.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.29 | 6.3% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $32.04 | 5.3% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $30.85 | 5.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $30.71 | 5.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.77 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.06 | 4.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.81 | 4.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.84 | 3.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.33 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.09 | 2.7% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $15.84 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.98 | 2.5% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $14.07 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.46 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $605.40 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $84.28 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $83.99 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.82 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $32.04 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.06 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.06 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 223 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
223 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1075 | 292 |
| Amlodipine Besylate | Amlodipine Besylate | 856 | 229 |
| Lisinopril | Lisinopril | 643 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 163 |
| Omeprazole | Omeprazole | 602 | 167 |
| Losartan Potassium | Losartan Potassium | 521 | 140 |
| Metformin Hcl | Metformin Hcl | 518 | 133 |
| Gabapentin | Gabapentin | 406 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 391 | 120 |
| Hydrochlorothiazide | Hydrochlorothiazide | 383 | 109 |
| Simvastatin | Simvastatin | 371 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 291 | 78 |
| Furosemide | Furosemide | 278 | 70 |
| Sertraline Hcl | Sertraline Hcl | 270 | 69 |
| Allopurinol | Allopurinol | 244 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 242 | 88 |
| Alprazolam | Alprazolam | 240 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 233 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 228 | 61 |
| Eliquis | Apixaban | 223 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 56 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 201 | 147 |
| Carvedilol | Carvedilol | 190 | 50 |
| Glipizide | Glipizide | 173 | 49 |
| Atenolol | Atenolol | 161 | 38 |
| Meloxicam | Meloxicam | 157 | 49 |
| Valsartan | Valsartan | 152 | 40 |
| Potassium Chloride | Potassium Chloride | 150 | 43 |
| Montelukast Sodium | Montelukast Sodium | 147 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 34 |
| Famotidine | Famotidine | 144 | 49 |
| Ozempic | Semaglutide | 144 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 62 |
| Jardiance | Empagliflozin | 132 | 31 |
| Prednisone | Prednisone | 130 | 86 |
| Trazodone Hcl | Trazodone Hcl | 125 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 34 |
| Tramadol Hcl | Tramadol Hcl | 116 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 28 |
| Alendronate Sodium | Alendronate Sodium | 104 | 29 |
| Warfarin Sodium | Warfarin Sodium | 100 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 25 |
| Lovastatin | Lovastatin | 92 | 25 |
| Meclizine Hcl | Meclizine Hcl | 91 | 27 |
| Finasteride | Finasteride | 88 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 23 |
| Ezetimibe | Ezetimibe | 84 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 21 |
| Benazepril Hcl | Benazepril Hcl | 69 | 17 |
| Glimepiride | Glimepiride | 69 | 18 |
| Glipizide Er | Glipizide | 69 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 16 |
| Spironolactone | Spironolactone | 67 | 21 |
| Mirtazapine | Mirtazapine | 65 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 24 |
| Lorazepam | Lorazepam | 64 | 18 |
| Mounjaro | Tirzepatide | 64 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 16 |
| Donepezil Hcl | Donepezil Hcl | 63 | 15 |
| Azithromycin | Azithromycin | 62 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 16 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Chlorthalidone | Chlorthalidone | 59 | 17 |
| Clonazepam | Clonazepam | 59 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 14 |
| Xarelto | Rivaroxaban | 52 | 13 |
| Celecoxib | Celecoxib | 51 | 16 |
| Januvia | Sitagliptin Phosphate | 51 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 21 |
| Buspirone Hcl | Buspirone Hcl | 47 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 13 |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Ramipril | Ramipril | 45 | 12 |
| Amoxicillin | Amoxicillin | 44 | 30 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 41 | 18 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 14 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Linzess | Linaclotide | 38 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 19 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Estradiol | Estradiol | 30 | 11 |
| Fluconazole | Fluconazole | 30 | 24 |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 16 |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Torsemide | Torsemide | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 14 |
| Baclofen | Baclofen | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | 12 |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Combipatch | Estradiol/Norethindrone Acet | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $605.40 · 34 records | Grifols USA, LLC | ACCRUFER, AREXVY, Cologuard Collection Kit, ELIQUIS, Exablate, GEMTESA, JARDIANCE, MONOFERRIC, NURTEC ODT, OTEZLA, Omnipod, PRECIVITYAD2, Prolastin-C Liquid, REPATHA, REXULTI, SHINGRIX, TZIELD, Tymlos, VOQUEZNA, WATCHMAN Access System, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error